AstraZeneca sales boosted by soaring demand for cancer treatments
AstraZeneca has reported a big enhance in sales for the primary half of 2026, pushed primarily by sturdy demand for its cancer and uncommon illness treatments, even because the pharmaceutical big elevated its funding in new analysis. The Cambridge-based agency noticed whole revenues climb 6% at fixed alternate charges to $30.67 billion (£22.99 billion). Its…
